Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01592370 · OUTCOME

Overall Survival

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma · Source last updated 2025-10-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Nivo Mono: approximately up to 6 years and 9 months Nivo Ipi: approximately up to3 years Nivo Liri: approximately up to 4 years 1 month

What was measured

The percentage of participants remaining alive. Median values are computed using Kaplan-Meier method

Analysis population: All Treated Participants with available measurements

Groups in this outcome

Nivolumab Monotherapy (Expansion)

3mg/kg of nivolumab

Nivolumab + Ipilimumab

3 mg/kg of nivolumab and 1 mg/kg of ipilimumab Q3W for 4 doses, followed by nivolumab alone at 3 mg/kg Q2W

Nivolumab + Lirilumab

3 mg/kg of nivolumab Q2W + 3 mg/kg of lirilumab Q4W

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Nivolumab Monotherapy (Expansion)104
Nivolumab + Ipilimumab65
Nivolumab + Lirilumab72

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Nivolumab Monotherapy (Expansion)52.57Not reported29.0NAUpper limit number not reached
Nivolumab + Ipilimumab30.39Not reported13.24NAupper limit number not reached
Nivolumab + Lirilumab14.95Not reported9.3634.23Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Upper limit number not reached
        group Id
        OG000
        lower Limit
        29.0
        upper Limit
        NA
        value
        52.57
      2. comment
        upper limit number not reached
        group Id
        OG001
        lower Limit
        13.24
        upper Limit
        NA
        value
        30.39
      3. group Id
        OG002
        lower Limit
        9.36
        upper Limit
        34.23
        value
        14.95
denoms
  1. counts
    1. group Id
      OG000
      value
      104
    2. group Id
      OG001
      value
      65
    3. group Id
      OG002
      value
      72
    units
    Participants
description
The percentage of participants remaining alive. Median values are computed using Kaplan-Meier method
dispersion Type
95% Confidence Interval
groups
  1. description
    3mg/kg of nivolumab
    id
    OG000
    title
    Nivolumab Monotherapy (Expansion)
  2. description
    3 mg/kg of nivolumab and 1 mg/kg of ipilimumab Q3W for 4 doses, followed by nivolumab alone at 3 mg/kg Q2W
    id
    OG001
    title
    Nivolumab + Ipilimumab
  3. description
    3 mg/kg of nivolumab Q2W + 3 mg/kg of lirilumab Q4W
    id
    OG002
    title
    Nivolumab + Lirilumab
param Type
MEDIAN
population Description
All Treated Participants with available measurements
reporting Status
POSTED
time Frame
Nivo Mono: approximately up to 6 years and 9 months Nivo Ipi: approximately up to3 years Nivo Liri: approximately up to 4 years 1 month
title
Overall Survival
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice